Multi-center clinical analysis on autologous and allogeneic hematopoietic stem cell transplantation in treatment of patients with natural killer/T cell lymphoma
方姝,王昭,付晓瑞,李乃农,胡亮钉,刘耀,董玉君,吴晓雄,王旖旎,张明智,李晓帆,李欲航,王买红,任汉云,吴亚妹,高春记,刘代红,黄文荣
DOI: https://doi.org/10.3760/cma.j.cn511693-20200612-00126-1
2021-01-01
Abstract:Objective:To explore difference of clinical effects and prognosis of autologous hematopoietic stem cell transplantation (auto-HSCT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in treatment of patients with natural killer/T cell lymphoma (NKTL).Methods:From June 2007 and June 2017, a total of 37 patients underwent auto-HSCT or allo-HSCT from 8 Chinese Grade Ⅲ class A teaching hospitals were selected as research subjects. The median ages of patients in auto-HSCT group and allo-HSCT group were 34.0 years(27.5-43.5 years) and 33.0 years (25.8-41.3 years), respectively. There were 10 male and 7 female patients in auto-HSCT group, and 17 male and 3 female patients in allo-HSCT group, respectively.According to hematopoietic stem cell transplantation (HSCT) types of patients underwent, all subjects were divided into auto-HSCT group ( n=17) and allo-HSCT group ( n=20). Then clinical data of NKTL patients in auto-HSCT group and allo-HSCT group were collected, and clinical effect and prognosis of patients in two groups were analyzed by retrospectively cohort method. Patients in both groups were followed up until December 31, 2017. Chi-square test or Fisher probabilities were used to compare categorical data between two groups, including composition ratios of clinical stages, marrow metastases, types of chemotherapy regimen and so on. Mann-Whitney U test was used to compare measurement data with skewed distribution, including age, transfusion amount of mononuclear cells (MNC) and CD34 + cells etc.. Kaplan-Meier method was used to draw survival curve of cumulative relapse, cumulative transplant-related mortality (TRM), overall survival (OS) and progression-free survival (PFS) of two groups, which were compared by log-rank test. Cox proportional hazards regression model was performed for univariate and multivariate analysis of OS rates between two groups. This study was in line with World Medical Association Declaration of Helsinki revised in 2013, and informed contents were obtained from all subjects. Results:① In auto-HSCT group, there were 12, 4, 1 and 0 patients evaluated as complete remission (CR), partial remission (PR), stable disease (SD) and progressive disease (PD) before HSCT, respectively. There were 4, 11, 1 and 4 cases in allo-HSCT group, respectively.There were significant differences among composition ratios of bone marrow metastase, disease states before HSCT and types of conditioning regimen ( P=0.001; χ2=12.087, P=0.016; χ2=23.632, P<0.001) between two groups. ② In auto-HSCT group, all 17 NKTL patients had successful neutrophil and platelet engraftment, and median engraftment time were 11.0 d (9.5-11.0 d) and 11.0 d (9.5-14.0 d), respectively. In allo-HSCT group, there were 18 NKTL patients with sucsessful neutrophil and platelet engraftment, and median engraftment time were 15.0 d (13.0-16.0 d) and 16.0 d(13.0-20.3 d), respectively. There was no significant difference in 3-year cumulative TRM (6.2% vs 23.7%; χ2=1.658, P=0.198) between two groups. ③ There were 13, 6 and 9 patients with graft versus host disease (GVHD), acute GVHD (aGVHD) and chronic GVHD (cGVHD), respectively. Patients with GVHD acquired effective control and improved of GVHD-related clinical symptoms after therapy. ④ There were no significant differences in 3-year cumulative relapsed rates (35.5% vs 48.1%; χ2=0.796, P=0.372) and 2-year PFS rates (64.8% vs 43.1%; χ2=2.765, P=0.096) between two groups, but 2-year OS rate in auto-HSCT group was significantly higher than that of allo-HSCT group (82.0% vs 41.3%; χ2=4.697, P=0.03). ⑤ The results of multivariate Cox proportional hazard regression analysis showed that underwent allo-HSCT was not an independent risk factor influencing OS rate of NKTL patients ( HR=4.618, 95% CI: 0.992-21.497, P=0.051). Conclusions:Auto-HSCT and allo-HSCT are both effective therapeutic methods for NKTL patients. OS rate of NKTL patients who acquire CR before HSCT could be improved by auto-HSCT, and disease state of patients who are relapsed or refractory can be controlled by allo-HSCT. However, this study is analysis by retrospective mothod, and sample size is limited, so the differences in efficacy and prognosis between auto-HSCT and allo-HSCT in treatment of NKTL patients needs to be further confirmed by prospective, large sample size and clinical randomized controlled studies.